CNS Pharmaceuticals (NASDAQ: CNSP) is working to determine the efficacy of its lead drug candidate, Berubicin, for the treatment of glioblastoma multiforme (“GBM”), an aggressive type of brain cancer for which there is currently no cure. Promising results were demonstrated when another company completed a small Phase 1 trial well over a decade ago in which 44% of patients saw their disease stabilize or improve. One Berubicin patient was living cancer-free as of the most recent medical assessment in November, nearly 15 years after the Phase 1 trial (https://ibn.fm/JnFSS). “CNS now hopes to advance Berubicin to commercial production, with the start of its potentially pivotal clinical trial slated to begin this quarter,” reads a recent article discussing the novel anthracycline that appears to cross the blood-brain barrier. “The global trial will compare Berubicin’s response to the effectiveness level of established chemotherapy drug lomustine in 243 GBM patients at about 35 clinical sites in the United States (https://ibn.fm/Wo3d9) and 25 more in foreign locations.”
To view the full article, visit https://ibn.fm/vWnGx
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
